EA202091182A1 - АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА - Google Patents

АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА

Info

Publication number
EA202091182A1
EA202091182A1 EA202091182A EA202091182A EA202091182A1 EA 202091182 A1 EA202091182 A1 EA 202091182A1 EA 202091182 A EA202091182 A EA 202091182A EA 202091182 A EA202091182 A EA 202091182A EA 202091182 A1 EA202091182 A1 EA 202091182A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hutnfr1
alcoholic
steathepatitis
therapy
nash
Prior art date
Application number
EA202091182A
Other languages
English (en)
Inventor
Хайке Бантель
Клаус Пфиценмайер
Андреас Херрманн
Original Assignee
Балиофарм Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Балиофарм Аг filed Critical Балиофарм Аг
Publication of EA202091182A1 publication Critical patent/EA202091182A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Антитело, специфически распознающее человеческий рецептор-1 фактора некроза опухолей (huTNFR1), для применения при лечении неалкогольного стеатогепатита (NASH) и связанных с ним заболеваний.
EA202091182A 2017-11-27 2018-11-27 АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА EA202091182A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17203853 2017-11-27
PCT/EP2018/082634 WO2019102023A1 (en) 2017-11-27 2018-11-27 ANTI-huTNFR1 THERAPY OF NONALCOHOLIC STEATOHEPATITIS

Publications (1)

Publication Number Publication Date
EA202091182A1 true EA202091182A1 (ru) 2020-07-29

Family

ID=60473433

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091182A EA202091182A1 (ru) 2017-11-27 2018-11-27 АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА

Country Status (14)

Country Link
US (1) US11028178B2 (ru)
EP (1) EP3717068A1 (ru)
JP (1) JP7280259B2 (ru)
KR (1) KR20200089699A (ru)
CN (1) CN111787980A (ru)
AU (1) AU2018371232A1 (ru)
BR (1) BR112020010632A2 (ru)
CA (1) CA3081493A1 (ru)
EA (1) EA202091182A1 (ru)
IL (1) IL274770A (ru)
MX (1) MX2020005445A (ru)
SG (1) SG11202003910VA (ru)
TW (1) TW201925234A (ru)
WO (1) WO2019102023A1 (ru)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006269A1 (de) 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
AU2006315758A1 (en) * 2005-11-10 2007-05-24 Ercole Biotech, Inc. Splice switching oligomers for TNF superfamily receptors and their use in treatment of disease
EP1972637B1 (en) * 2007-03-19 2011-06-29 Universität Stuttgart huTNFR1 selective antagonists
US8859739B2 (en) * 2010-09-16 2014-10-14 Baliopharm Ag Anti-huTNFR1 antibody and methods of use thereof for treatment
JP6622591B2 (ja) * 2013-03-06 2019-12-18 プロタリクス リミテッド ＴＮＦαポリペプチド阻害薬を発現する植物細胞の、治療法における使用
BR112018070452A2 (pt) * 2016-04-05 2019-02-05 Baliopharm Ag um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico

Also Published As

Publication number Publication date
AU2018371232A1 (en) 2020-05-21
JP2021504379A (ja) 2021-02-15
JP7280259B2 (ja) 2023-05-23
US11028178B2 (en) 2021-06-08
BR112020010632A2 (pt) 2020-11-10
MX2020005445A (es) 2020-10-28
EP3717068A1 (en) 2020-10-07
US20200299396A1 (en) 2020-09-24
IL274770A (en) 2020-07-30
CN111787980A (zh) 2020-10-16
TW201925234A (zh) 2019-07-01
SG11202003910VA (en) 2020-06-29
WO2019102023A1 (en) 2019-05-31
KR20200089699A (ko) 2020-07-27
CA3081493A1 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
CY1123256T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
EA201692050A1 (ru) Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита
PH12020552229A1 (en) Il-11ra antibodies
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MX2021000392A (es) Anticuerpos anti-mesotelina.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
CL2019000846A1 (es) Proteína terapéutica.
MX2020005473A (es) Anticuerpos humanizados que se dirigen al factor tisular humano.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
NZ762312A (en) Anti-pacap antibody
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
TR201908138T4 (tr) Bir anti-her2 antikoru ilaç konjügatı ve bir bcl-2 inhibitörü ile kombinasyon terapisi.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы